- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05593770
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response (NECTAR)
International Sites: CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. The clinical spectrum of COVID-19 infection is broad, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and death. Between 13 and 40% of patients become hospitalized, up to 30% of those hospitalized require admission for intensive care, and there is a 13% inpatient mortality rate. The reasons for hospitalization include respiratory support, as well as support for failure of other organs, including the heart and kidneys. The risk of thrombotic complications is increased, even when compared to other viral respiratory illnesses, such as influenza. While 82% of hospitalized patients with COVID-19 are ultimately discharged alive, median length of stay is 10-13 days.
Early work in treating COVID-19 has focused on preventing worsening of the initial clinical presentation to prevent hospitalization and disease progression to organ failure and death. Studies conducted under this Master Host Tissue Protocol are expected to extend our knowledge of how to manage patients who are hospitalized for COVID-19 illness. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19. This Master Protocol is a randomized, placebo-controlled trial of agents targeting the host response in COVID-19 in hospitalized patients with hypoxemia. The Master Host Tissue Protocol is designed to be flexible in the number of study arms, the use of a single placebo group, and the stopping and adding of new therapies. Our primary outcome is oxygen free days through day 28. This is defined as days alive and without supplemental oxygen use during the first 28 days following randomization. Patients who die on or before day 28 are assigned -1 oxygen free days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: NECTAR Project Manager
- Phone Number: +44 (0) 7494 795 982
- Email: nectar@rokcservices.com
Study Locations
-
-
-
Porto Alegre, Brazil
- Hospital de Clínicas de Porto Alegre
-
Rio De Janeiro, Brazil
- Hospital Federal dos Servidores do Estado
-
Rio De Janeiro, Brazil
- Instituto Nacional de Infectologia Evandro Chagas
-
-
-
-
-
Bonn, Germany
- University Hospital Bonn
-
Frankfurt, Germany
- University of Frankfurt
-
-
-
-
-
Genova, Italy
- Ente Ospedaliero Ospedali Galliera
-
Milan, Italy
- University of Milan
-
Milan, Italy
- San Paolo Hospital - ASST Santi Paolo e Carlo
-
Milan, Italy
- San Raffaele Turro Hospital
-
-
-
-
-
Benoni, South Africa
- Worthwhile Clinical Trials (WWCT Lakeview Hospital)
-
Johannesburg, South Africa
- Clinical HIV Research Unit - Helen Joseph Hospital (WITS CHRU)
-
Pretoria, South Africa
- Global Clinical Trials (Pty) Ltd
-
-
-
-
-
Alicante, Spain
- Hospital General Universitario de Elche
-
Barcelona, Spain
- Hospital del Mar
-
Barcelona, Spain
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain
- Hospital Clinico San Carlos
-
Madrid, Spain
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain
- Hospital Universitario Fundacion Alcorcon
-
Valladolid, Spain
- Universidad de Valladolid - Hospital Universitario Río Hortega
-
Zaragoza, Spain
- Hospital Clinico Universitario Lozano Blesa
-
-
Villarroel
-
Barcelona, Villarroel, Spain
- Hospital Clinic Barcelona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hospitalized for COVID-19
- ≥18 years of age
SARS-CoV-2 infection, documented by:
- nucleic acid test (NAT) or equivalent testing within 3 days prior to randomization OR
- documented by NAT or equivalent testing more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the responsible investigator (For non-NAT tests, only those deemed with equivalent specificity to NAT by the protocol team will be allowed. A central list of allowed non- NAT tests is maintained in Appendix E. Appendix E. Non-NAT Tests Deemed with Equivalent Specificity to NAT by the Protocol Team).
- Hypoxemia, defined as SpO2 <92% on room air, new receipt of supplemental oxygen to maintain SpO2 ≥92%, or increased supplemental oxygen to maintain SpO2 ≥92% for a patient on chronic oxygen therapy
Symptoms or signs of acute COVID-19, defined as one or more of the following:
- cough
- reported or documented body temperature of 100.4 degrees Fahrenheit or greater
- shortness of breath
- chest pain
- infiltrates on chest imaging (x-ray, CT scan, lung ultrasound)
Exclusion Criteria:
- Onset of COVID-19 symptom fulfilling inclusion criterion #5 >14 days prior to randomization
- Hospitalized with hypoxemia (as defined in inclusion #4) for >72 hours prior to randomization (the 72-hour window for randomization begins when the patient first meets the hypoxemia inclusion criteria after hospital admission)
- Pregnancy
- Breastfeeding
- Prisoners
- End-stage renal disease (ESRD) on dialysis
- Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life.
- The treating clinician expects inability to participate in study procedures or participation would not be in the best interests of the patient
- Known allergy/hypersensitivity to IMP or its excipients
Fostamatinib Arm-Specific Exclusion Criteria:
The following exclusion criteria differ from the master protocol criteria:
1. Randomized in another trial evaluating fostamatinib in the prior 30 days
Study arm exclusion criteria measured within 24 hours prior to randomization:
- AST or ALT ≥ 5 × upper limit of normal (ULN) or ALT or AST ≥ 3 × ULN and total bilirubin ≥ 2 × ULN
- SBP > 160 mmHg or DBP > 100 mmHg at the time of screening and randomization
- ANC < 1000/mL
- Patient is anticipated to require a strong CYP3A inhibitor (Atazanavir, Certinib, Clarithromycin, Cobicistat and cobicistat-containing coformulations, Idelalisib,Indinavir, Itraconazole, Ketoconazole, Levoketoconazole, Lonafarnib, Lopinavir, Mifeprostone, Mibefradil, Nefazodone, Nelfinavir, Ombitasvir-paritaprevir-ritonavir plus dasabuvir, Posaconazole, Ribociclib Ritonavir, Saquinavir, Telithromycin, Troleandomycin, Tucatinib, Voriconazole) from randomization to 21 days post-randomization. For a full list of CYP3A4 substrates, please reference this regularly updated list: https://drug-interactions.medicine.iu.edu/MainTable.aspx.
- Patient unable to participate or declines participation in the fostamatinib arm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fostamatinib
An investigational oral spleen tyrosine kinase inhibitor.
|
Fostamatinib100-150mg orally twice daily for 14 days or 28 doses.
Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
|
Placebo Comparator: Placebo
Orange film-coated, plain, bioconvex tablets for fostamatinib. For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included. |
Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib.
Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxygen free days through day 28
Time Frame: Day 1 to Day 28
|
This is defined as days alive and without supplemental oxygen use during the first 28 days following randomization.
Patients who die on or before day 28 are assigned -1 oxygen free days.
Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
|
Day 1 to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital mortality
Time Frame: Day 1 to hospital discharge or Day 90 whichever comes first
|
Proportion of patients who die during hospitalization
|
Day 1 to hospital discharge or Day 90 whichever comes first
|
Alive and oxygen free at Day 14
Time Frame: Day 1 to Day 14
|
Proportion of patients oxygen free at day 14.
Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
|
Day 1 to Day 14
|
Alive and oxygen free at Day 28
Time Frame: Day 1 to Day 28
|
Proportion of patients oxygen free at day 28.
Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO)
|
Day 1 to Day 28
|
Alive and free of new invasive mechanical ventilation at day 28
Time Frame: Day 1 to Day 28
|
Proportion of patients alive free of new invasive mechanical ventilation at day 28
|
Day 1 to Day 28
|
28-day mortality
Time Frame: Day 28
|
Proportion of patients alive at Day 28
|
Day 28
|
60-day mortality
Time Frame: Day 60
|
Proportion of patients alive at Day 60
|
Day 60
|
90-day mortality
Time Frame: Day 90
|
Proportion of patients alive at Day 90
|
Day 90
|
Clinical status assessed using World Health Organization (WHO) 8-point ordinal scale at Day 14
Time Frame: Day 14
|
|
Day 14
|
Clinical status assessed using WHO 8-point ordinal scale at Day 28
Time Frame: Day 28
|
|
Day 28
|
Clinical status assessed using WHO 8-point ordinal scale at Day 60
Time Frame: Day 60
|
|
Day 60
|
Hospital-free days through day 28
Time Frame: Day 1 to Day 28
|
Days alive and not hospitalized during the first 28 days following randomization.
Patients who die on or before day 28 are assigned a value -1.
|
Day 1 to Day 28
|
Ventilator-free days through day 28
Time Frame: Day 1 to Day 28
|
Days alive and not receiving mechanical ventilation during the first 28 days following randomization.
Patients who die on or before day 28 are assigned a value -1.
|
Day 1 to Day 28
|
Respiratory failure-free days through day 28
Time Frame: Day 1 to Day 28
|
Days alive and not in respiratory failure during the first 28 days following randomization.
A respiratory failure-free day is defined as a day alive without the use of HFNC, NIV, IMV, or (ECMO).
Patients who die on or before day 28 are assigned a value -1.
|
Day 1 to Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anton Pozniak, Prof, NEAT ID
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTIV-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Fostamatinib
-
Fundación Pública Andaluza para la gestión de la...CompletedPrimary Immune ThrombocytopeniaSpain
-
Rigel PharmaceuticalsCompletedPneumonia, Viral | Pneumonia | Covid19 | SARS (Severe Acute Respiratory Syndrome) | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | SARS PneumoniaUnited States, Argentina, Brazil, Mexico
-
Rigel PharmaceuticalsCompleted
-
AstraZenecaCompletedHealthy Japanese VolunteersUnited States
-
Rigel PharmaceuticalsCompletedImmune Thrombocytopenic PurpuraUnited States, Australia, United Kingdom, Canada, Italy, Denmark, Hungary, Netherlands
-
Rigel PharmaceuticalsCompletedImmune Thrombocytopenic PurpuraSpain, United States, Australia, Poland, United Kingdom, Canada, Czechia, Bulgaria, Romania, Austria, Denmark, Hungary, Italy, Netherlands, Norway
-
Rigel PharmaceuticalsNo longer availableImmune Thrombocytopenic Purpura
-
Rigel PharmaceuticalsCompletedImmune Thrombocytopenic PurpuraSpain, Norway, Poland, Czechia, Germany, United States, Austria, Bulgaria, Romania
-
Rigel PharmaceuticalsWithdrawn
-
Rigel PharmaceuticalsTerminatedImmune Thrombocytopenia | ITPUnited States